SCHEMBL25979783

SCHEMBL25979783

c1ccc(-c2ccc(N(c3ccccc3)c3ccc4c(c3)oc3cc(-c5nc(-c6ccccc6)nc(-c6ccc7ccccc7c6)n5)ccc34)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
CYP1A2 P05177 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 2/20 0.42
TP53 P04637 1/20 0.42
NOTUM Q6P988 1/20 0.35
MAPT P10636 3/20 0.34
NR1H4 Q96RI1 1/20 0.34
CYP1A1 P04798 2/20 0.34
CYP1B1 Q16678 2/20 0.34
PGR P06401 1/20 0.34
HPGD P15428 3/20 0.33
PTGES O14684 1/20 0.33
ALOX5 P09917 1/20 0.33
AHR P35869 1/20 0.33
UTRN P46939 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26779281 1.00 ALDH1A1 (0.42) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL25979930 0.99 CYP1A2 (0.41) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL25979801 0.99 CYP1A2 (0.40) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL25979483 0.96 MEN1 (0.40) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL25979457 0.96 MEN1 (0.40) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL25979640 0.95 ALDH1A1 (0.39) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL26779139 0.94 ALDH1A1 (0.39) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL25979849 0.94 CYP1A1 (0.43) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL26779239 0.94 MEN1 (0.40) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL25979513 0.94 MAPT (0.37) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 ALDH1A1 9/4885CYP1A2 5/4885SMN1; SMN2 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.